 This is a two part, open-label, non-randomized trial that will be conducted at Thomas Jefferson University TJU. Initially in Part 1, a two-period, crossover, dose-finding study will be performed in 12 healthy female volunteers to determine the optimal dose as well as the safety and tolerability of the tissue-specific, contrast agent Sonazoid GE Healthcare, Oslo, Norway for human lymphatic applications. Each volunteer will receive an injection of a low or a high dose in a blinded, sequence-randomized allocation schedule. Screening and baseline assessmentsprocedures will be obtained. Each volunteer will receive their subdermal, low or high dose of Sonazoid divided into four individual aliquots at four locations 12, 3, 6, and 9 oclock around a 2 cm in diameter region in the mid-upper outer quadrant of the left breast. 